C84.60
Anaplastic large cell lymphoma, ALK-positive, unspecified site
Clinical Classification Guidelines
Medical Intelligence & Overview
Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma that originates from T-cells, a type of immune system cell. When characterized as ALK-positive, it means that the cancer cells contain a specific mutation in the anaplastic lymphoma kinase (ALK) gene, which plays a role in cell growth. This form of lymphoma can occur at various sites in the body, but in this case, it is unspecified, indicating that the primary location of the lymphoma has not been firmly identified. ALK-positive ALCL generally affects children and young adults and is known for its relatively favorable response to treatment compared to other lymphomas.
Causes & Symptoms
Clinical Causes: Genetic mutations, particularly involving the ALK gene. No clear lifestyle or environmental cause has been established.
Key Symptoms: Swollen lymph nodes, often painless. Fever that persists over time. Night sweats and unexplained weight loss. Fatigue and general malaise. Mediastinal mass or chest discomfort (if in chest area). Skin lesions or rashes if the disease involves the skin. Other systemic symptoms such as itching or itching-like skin sensations.
Diagnostic & Treatment
Diagnosis Path: Physical examination to check for swollen lymph nodes and other signs. Biopsy of affected tissue to identify lymphoma cells and determine ALK status. Imaging tests such as PET scans, CT scans, or MRI to locate involved sites. Blood tests to assess overall health and organ function. Molecular testing to confirm ALK gene rearrangement. Additional tests like bone marrow biopsy if systemic spread is suspected.
Treatment Protocols: Chemotherapy: A combination of drugs designed to target and destroy cancer cells. Targeted therapy: Use of ALK inhibitors that specifically block the activity of the ALK protein involved in cancer growth. Radiation therapy: Applied in specific cases to eliminate localized disease or relieve symptoms. Stem cell transplant: May be considered in cases where initial treatments do not lead to remission. Supportive care: Managing symptoms and side effects with medications and supportive therapies. Regular follow-up: To monitor for treatment response and detect any recurrence or progression of the disease.
Clinical Advice & FAQs
Billing Guidance
Is C84.60 a billable ICD-10 code?
Yes, C84.60 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C84.60?
Clinical documentation must specify the nature of Anaplastic large cell lymphoma, ALK-positive, unspecified site and any associated comorbidities for accurate reporting.
Cite this Clinical Reference